Citius Pharmaceuticals, Inc. (CTXR) stock
CTXRNasdaqPharmaceutical PreparationsFiscal year ends September 30
$0.51−0.01 (-1.56%)
Close on Nov 18, 2026Market cap $14.02MP/E –Yield –
Citius Pharmaceuticals net income
Net income is the profit left for shareholders after every expense, interest and tax.
Citius Pharmaceuticals's net income for the twelve months ending Jun 30, 2024 was -$19.83M. For fiscal 2023 it was -$32.54M. The highest annual figure on record is -$22.01K in fiscal 2012.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Sep 30, 2023 | -$32.54M | – |
| FY2022 | Sep 30, 2022 | -$33.64M | – |
| FY2021 | Sep 30, 2021 | -$23.05M | – |
| FY2020 | Sep 30, 2020 | -$17.55M | – |
| FY2019 | Sep 30, 2019 | -$15.56M | – |
| FY2018 | Sep 30, 2018 | -$12.54M | – |
| FY2017 | Sep 30, 2017 | -$10.38M | – |
| FY2016 | Sep 30, 2016 | -$8.30M | – |
| FY2012 | Sep 30, 2012 | -$22.01K | – |
| FY2011 | Sep 30, 2011 | -$26.34K | – |
Quarterly net income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$11.51M | -224.7% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$10.28M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$10.57M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$8.54M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $9.23M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$9.94M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$3.59M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$7.99M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$8.86M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$7.56M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$9.23M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$4.96M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$5.82M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$4.12M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$8.15M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$4.12M | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$4.68M | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$4.42M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$4.32M | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$3.65M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$4.41M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$3.63M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$3.87M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$2.85M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$2.02M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$4.42M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$3.25M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$3.04M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$2.42M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$2.74M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$2.18M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$2.59M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -$3.62M | – |
See a number that looks wrong?